{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:13:56Z","timestamp":1787591636157,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.imlet.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:17:48Z","timestamp":1573125468000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The role of toll-like receptors in myocardial toxicity induced by doxorubicin"],"prefix":"10.1016","volume":"217","author":[{"given":"Cai","family":"Xinyong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Zhiyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Xiaocheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.imlet.2019.11.001_bib0005","first-page":"241","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy \u2014 an update","volume":"818","author":"Renu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.imlet.2019.11.001_bib0010","article-title":"The role of autophagy in the heart","author":"Nishida","year":"2008","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0015","first-page":"78","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters Karlijn","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0020","first-page":"0","article-title":"Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes","volume":"302","author":"Gilliam Laura","year":"2011","journal-title":"Am. J. Physiol., Cell Physiol."},{"issue":"28","key":"10.1016\/j.imlet.2019.11.001_bib0025","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0030","first-page":"7","article-title":"Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis","volume":"7","author":"Wallace Kendall","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0035","first-page":"42","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"25","author":"Sui","year":"2012","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.imlet.2019.11.001_bib0040","first-page":"842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"62","author":"Shiwei","year":"2014","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.imlet.2019.11.001_bib0045","first-page":"46","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Yi-Lisa","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.imlet.2019.11.001_bib0050","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0055","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41598-018-37862-3","article-title":"Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration","volume":"9","author":"Abdullah-Chowdhury","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.imlet.2019.11.001_bib0060","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1096\/fj.201802663R","article-title":"Doxorubicin-induced cardiomyocyte death is mediatedby unchecked mitochondrial fission and mitophagy","volume":"33","author":"Catanzaro-Michael","year":"2019","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0065","first-page":"2308","article-title":"Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart","volume":"4","author":"Atsushi","year":"2013","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0070","article-title":"Respiratory chain deficiency precedes the disrupted calcium homeostasisin chronic doxorubicin cardiomyopathy","volume":"19","author":"Dirk","year":"2009","journal-title":"Elsevier Inc."},{"issue":"18","key":"10.1016\/j.imlet.2019.11.001_bib0075","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-14-0821","article-title":"Twisting and ironing doxorubicin cardiotoxicity by mitochondrial DNA damage","volume":"20","author":"Nitiss","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.imlet.2019.11.001_bib0080","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","article-title":"Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management","volume":"8","author":"Barry","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.imlet.2019.11.001_bib0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-009-0051-8","article-title":"Cardiomyocyte death in doxoru-bicin-induced cardiotoxicity","volume":"57","author":"Zhang","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction inthe trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6640","key":"10.1016\/j.imlet.2019.11.001_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"issue":"6996","key":"10.1016\/j.imlet.2019.11.001_bib0100","first-page":"63","article-title":"Beutler Bruce. Inferences, questions and possibilities in Toll-like receptor signalling","volume":"430","year":"2004","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0105","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.bbadis.2015.08.013","article-title":"Toll-like receptor 5 deficiency attenuates interstitial cardiac fibrosis and dysfunction induced by pressure overload by inhibiting inflammation and the endothelial-mesenchymal transition","volume":"1852","author":"Zhang","year":"2015","journal-title":"BBA) Molecular Basis of Disease"},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cardiores.2006.09.011","article-title":"Toll-like Receptor Stimulation in Cardiomyoctes Decreases Contractility and Initiates an Nf-kappab Dependent Inflammatory Response","volume":"72","author":"Walley","year":"2006","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1146\/annurev-biochem-052909-141507","article-title":"Structural Biology of the Toll-Like Receptor Family","volume":"80","author":"Kang","year":"2011","journal-title":"Annu. Rev. Biochem."},{"issue":"12","key":"10.1016\/j.imlet.2019.11.001_bib0120","first-page":"66","article-title":"Targeting Toll-like receptors with small molecule agents","volume":"44","author":"Xiaohui","year":"2013","journal-title":"Chem. Soc. Rev."},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/db08-0564","article-title":"High glucose induces toll-like receptor expression in human monocytes: mechanism of activation","volume":"57","author":"Dasu","year":"2008","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0130","first-page":"1546","article-title":"Neutralization of interleukin-1\u03b2 in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling","volume":"85","author":"Sasayama","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2079","article-title":"The Family of Five: Tir-domain-containing adaptors in toll-like receptor signalling","volume":"7","author":"Bowie","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0140","first-page":"985","article-title":"Blockade of Myd88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo","volume":"36","author":"Kao","year":"2006","journal-title":"Am. J. Physiol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2006.02.024","article-title":"Caught in the act: in vivo molecular imaging of the transcription factor nf-kappab after myocardial infarction","volume":"342","author":"Ertl","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.imlet.2019.11.001_bib0150","doi-asserted-by":"crossref","first-page":"10162","DOI":"10.1073\/pnas.160027697","article-title":"A46r and A52r from vaccinia virus are antagonists of host Il-1 and toll-like receptor signaling","volume":"97","author":"O\u2019neill","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0155","first-page":"4","article-title":"Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury","volume":"72","author":"Spring","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0160","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1086\/320712","article-title":"In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like Receptor-4","volume":"183","author":"Vallejo","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"20","key":"10.1016\/j.imlet.2019.11.001_bib0165","first-page":"15","article-title":"Cd14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction","volume":"106","author":"Vallejo","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.imlet.2019.11.001_bib0170","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.0000144175.70140.8c","article-title":"Immune cell toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia","volume":"95","author":"Tavener","year":"2004","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0175","first-page":"1335","article-title":"Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis","volume":"6","author":"Wei","year":"2010","journal-title":"Crit. Care Med."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/ajpheart.00995.2008","article-title":"Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart","volume":"296","author":"Chao","year":"2008","journal-title":"Ajp Heart Circ. Physiol."},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0185","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.4049\/jimmunol.178.11.7317","article-title":"Protection against myocardial ischemia\/reperfusion injury in Tlr4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism","volume":"178","author":"Li","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0190","first-page":"10","article-title":"Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury","volume":"36","author":"Mann","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.imlet.2019.11.001_bib0195","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/01.CIR.0000112575.66565.84","article-title":"Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice","volume":"109","author":"Todd","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.109.880187","article-title":"Myocardial Ischemia\/reperfusion injury is mediated by leukocytic toll-like Receptor-2 and reduced by systemic administration of a novel anti-toll-like Receptor-2 antibody","volume":"121","author":"Gerard","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0205","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.bbrc.2005.10.068","article-title":"Blocking the Myd88-dependent pathway protects the myocardium from ischemia\/reperfusion injury in rat hearts","volume":"338","author":"Li","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.imlet.2019.11.001_bib0210","doi-asserted-by":"crossref","unstructured":"J B. Tissue-specific Effects of the Nuclear Factor Kappab Subunit P50 on Myocardial Ischemia-reperfusion Injury. The American Journal of Pathology, 2007, 171(2): 507-512.","DOI":"10.2353\/ajpath.2007.061042"},{"issue":"12","key":"10.1016\/j.imlet.2019.11.001_bib0215","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.4049\/jimmunol.176.12.7154","article-title":"Cutting edge: high-mobility group Box 1 preconditioning protects against liver ischemia-reperfusion injury","volume":"176","author":"Geller","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0220","first-page":"75","article-title":"Preconditioning with a Tlr2 specific ligand increases resistance to cerebral Ischemia\/reperfusion injury","volume":"199","author":"Li","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0225","first-page":"0","article-title":"Innate immunity mediates myocardial preconditioning through toll-like receptor 2 and tirap-dependent signaling pathways","volume":"298","author":"Mann","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0230","first-page":"903","article-title":"Preconditioning by toll-like receptor 2 agonist Pam3csk4 reduces Cxcl1-dependent leukocyte recruitment in murine myocardial ischemia\/reperfusion injury","volume":"56","author":"Claycomb","year":"2010","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.imlet.2019.11.001_bib0235","first-page":"41","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Packer","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.imlet.2019.11.001_bib0240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.physiol.65.092101.142249","article-title":"Stress-activated cytokines and the heart: from adaptation to maladaptation","volume":"65","author":"Dl","year":"2003","journal-title":"Annu. Rev. Physiol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI6709","article-title":"Toll4 (tlr4) expression in cardiac myocytes in normal and failing myocardium","volume":"104","author":"Kelly","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCRESAHA.107.158220","article-title":"Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction","volume":"102","author":"Quax","year":"2008","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.imlet.2019.11.001_bib0260","article-title":"Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction","volume":"108","author":"Mitsunori","year":"2002","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1053-2498(03)00106-2","article-title":"Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices","volume":"23","author":"Yacoub","year":"2004","journal-title":"J. Heart. Lung. Transplant."},{"key":"10.1016\/j.imlet.2019.11.001_bib0270","first-page":"34","article-title":"Innate immunity in the adult mammalian heart: for whom the cell tolls","volume":"121","author":"Barger","year":"2010","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"4","key":"10.1016\/j.imlet.2019.11.001_bib0275","first-page":"1900","article-title":"Myd88 and Nos2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes","volume":"10","author":"Chao","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.imlet.2019.11.001_bib0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI6709","article-title":"Toll4 (TLR4) expression in cardiacmyocytes in normal and failing myocardium","volume":"104","author":"Frantz","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/ajpheart.00292.2009","article-title":"Myocardial TLR4 is a determinant of neutrophil in\ufb01ltrationafter global myocardial ischemia: mediating KC and MCP1 expression induced by extracellular HSC70","volume":"297","author":"Ao","year":"2009","journal-title":"Am. J. PhysiolHeart Circ. Physiol."},{"key":"10.1016\/j.imlet.2019.11.001_bib0290","doi-asserted-by":"crossref","first-page":"I-270","DOI":"10.1161\/CIRCULATIONAHA.105.000901","article-title":"In-hibition of toll-like receptor 4 with eritoran attenuatesmyocardial ischemia-reperfusion injury","volume":"114","author":"Shimamoto","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.athoracsur.2008.01.043","article-title":"Cytokines link Toll-like recep-tor 4 signaling to cardiac dysfunction after global myocar-dial ischemia","volume":"85","author":"Cha","year":"2008","journal-title":"Ann. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/ajpheart.00995.2008","article-title":"Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart","volume":"296","author":"Chao","year":"2008","journal-title":"Ajp Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.imlet.2019.11.001_bib0305","first-page":"0","article-title":"Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia","volume":"48","author":"R","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"8","key":"10.1016\/j.imlet.2019.11.001_bib0310","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","article-title":"Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management","volume":"8","author":"Lipshultz","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0315","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm1203-1465","article-title":"Autoimmunity heats up","volume":"9","author":"Gelman Andrew","year":"2003","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0320","first-page":"43","article-title":"Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice","volume":"10","author":"Alexander","year":"2008","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Dass","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"8","key":"10.1016\/j.imlet.2019.11.001_bib0330","first-page":"63","article-title":"Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction","volume":"12","author":"Thor","year":"2006","journal-title":"J. Card. Fail."},{"issue":"7","key":"10.1016\/j.imlet.2019.11.001_bib0335","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1074\/jbc.M009160200","article-title":"Role of Tlr-2 in the activation of nuclear factor kappab by oxidative stress in cardiac myocytes","volume":"276","author":"Kelly","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.imlet.2019.11.001_bib0340","article-title":"TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure","author":"Shao","year":"2018","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0345","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1152\/ajpheart.00642.2006","article-title":"Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury","volume":"292","author":"Sakata","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.imlet.2019.11.001_bib0350","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.CCM.0000256723.37586.A2","article-title":"Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction","volume":"35","author":"Ulrich","year":"2007","journal-title":"Crit. Care Med."},{"issue":"18","key":"10.1016\/j.imlet.2019.11.001_bib0355","first-page":"2869","article-title":"Modulation of Doxorubicin-induced Cardiac Dysfunction in Toll-like Receptor-2-knockout Mice","volume":"110","author":"Isao","year":"2004","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"issue":"Pt 3","key":"10.1016\/j.imlet.2019.11.001_bib0360","first-page":"729","article-title":"Activation of nuclear factor-kappab during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide","volume":"367","author":"Balaraman","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.imlet.2019.11.001_bib0365","first-page":"9","article-title":"Investigation of Age, Their Receptor and Nf-kappab Activation and Apoptosis in Patients with Attr and Gelsolin Amyloidosis","volume":"6","author":"Anan","year":"2010","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0370","first-page":"11","article-title":"Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing Tlr4-triggered nuclear factor-kappa B activation","volume":"131","author":"Jian","year":"2014","journal-title":"Acta Haematol."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0375","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4103\/0253-7613.117729","article-title":"Effect of carvedilol on cardiomyocyte apoptosis in a rat model of myocardial infarction: a role for toll-like receptor 4","volume":"45","author":"Wu","year":"2013","journal-title":"Indian J. Pharmacol."},{"issue":"4","key":"10.1016\/j.imlet.2019.11.001_bib0380","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2006-06-028704","article-title":"Toll-like receptors and their ligands control mesenchymal stem cell functions","volume":"109","author":"Pevsner Fischer","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0385","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/stemcells.2007-0563","article-title":"Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses","volume":"26","author":"Ab","year":"2008","journal-title":"Stem Cells (Dayton, Ohio)"},{"issue":"409","key":"10.1016\/j.imlet.2019.11.001_bib0390","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aab2191","article-title":"Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use","volume":"9","author":"Sun","year":"2016","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0395","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/imr.12381","article-title":"Negative regulation of tlr signaling in myeloid cells-implications for autoimmune diseases","volume":"269","author":"Buckner","year":"2016","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.imlet.2019.11.001_bib0400","first-page":"22","article-title":"Anti-apoptotic serpins as therapeutics in cardiovascular diseases","volume":"13","author":"Bot","year":"2013","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0405","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13075-015-0833-9","article-title":"Fibronectin fragment-induced expression of matrix metalloproteinases is mediated by Myd88-dependent Tlr-2 signaling pathway in human chondrocytes","volume":"17","author":"Ha","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.imlet.2019.11.001_bib0410","first-page":"0","article-title":"Tlr-3 is present in human adipocytes, but its signalling is not required for obesity-induced inflammation in adipose tissue in vivo","volume":"10","author":"Stienstra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2019.11.001_bib0415","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0420","first-page":"30","article-title":"Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats","volume":"107","author":"Mccarthy Cameron","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.imlet.2019.11.001_bib0425","first-page":"4245","article-title":"CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis","volume":"233","author":"Deng-Cheng","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.imlet.2019.11.001_bib0430","first-page":"96","article-title":"CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia\/reperfusion injury: involving activation of PI3K\/Akt signaling","volume":"1832","author":"Zhijuan","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.imlet.2019.11.001_bib0435","article-title":"Toll-like receptor 9 prevents cardiac rupture after myocardial infarction in mice independently of inflammation","volume":"311","author":"Shigemiki","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.imlet.2019.11.001_bib0440","first-page":"1","article-title":"The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure","volume":"2018","author":"Lili","year":"2018","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2019.11.001_bib0445","first-page":"1","article-title":"Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice","volume":"2017","author":"Yangchen","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2019.11.001_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.yjmcc.2015.10.011","article-title":"Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling","author":"Lu","year":"2015","journal-title":"J. Mol. Cell. Cardiol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781930464X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781930464X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:36:37Z","timestamp":1759044997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524781930464X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":90,"alternative-id":["S016524781930464X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2019.11.001","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of toll-like receptors in myocardial toxicity induced by doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}